Siegel RL, Miller KD, Jemal A. Most cancers statistics, 2020. CA A Most cancers J Clin. 2020;70:7–30.
Siegel RL, Miller KD, Jemal A. Most cancers Statistics, 2017. CA A Most cancers J Clin. 2017;67:7–30.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal most cancers statistics, 2017. CA A Most cancers J Clin. 2017;67:177–93.
Leitner A, Joachimiak LA, Bracher A, Monkemeyer L, Walzthoeni T, Chen B, et al. The molecular structure of the eukaryotic chaperonin TRiC/CCT. Construction. 2012;20:814–25.
Meyer AS, Gillespie JR, Walther D, Millet IS, Doniach S, Frydman J. Closing the folding chamber of the eukaryotic chaperonin requires the transition state of ATP hydrolysis. Cell. 2003;113:369–81.
Balchin D, Hayer-Hartl M, Hartl FU. In vivo elements of protein folding and high quality management. Science. 2016;353:aac4354.
Balchin D, Milicic G, Strauss M, Hayer-Hartl M, Hartl FU. Pathway of actin folding directed by the eukaryotic chaperonin TRiC. Cell. 2018;174:1507–21.e1516.
Gestaut D, Roh SH, Ma B, Pintilie G, Joachimiak LA, Leitner A, et al. The chaperonin TRiC/CCT associates with prefoldin via a conserved electrostatic interface important for mobile proteostasis. Cell. 2019;117:751–65.e15.
Yao L, Zou X, Liu L. The TCP1 ring advanced is related to malignancy and poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2019;12:3329–43.
Li W, Liu J, Zhao H. Prognostic energy of a chaperonin containing TCP-1 subunit genes panel for hepatocellular carcinoma. Entrance Genetics. 2021;12:668871.
Visitor ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP. Two members of the TRiC chaperonin advanced, CCT2 and TCP1 are important for survival of breast most cancers cells and are linked to driving oncogenes. Exp cell Res. 2015;332:223–35.
Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI. Characterization and over-expression of chaperonin t-complex proteins in colorectal most cancers. J Pathol. 2006;210:351–7.
Yin H, Miao X, Wu Y, Wei Y, Zong G, Yang S, et al. The function of the Chaperonin containing t-complex polypeptide 1, subunit 8 (CCT8) in B-cell non-Hodgkin’s lymphoma. Leukemia Res. 2016;45:59–67.
Xiang B, Chatti Okay, Qiu H, Lakshmi B, Krasnitz A, Hicks J, et al. Brk is coamplified with ErbB2 to advertise proliferation in breast most cancers. Proc Natl Acad Sci USA. 2008;105:12463–8.
Roskoski R Jr. ERK1/2 MAP kinases: construction, operate, and regulation. Pharmacol Res. 2012;66:105–43.
Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-beta signaling. J Clin Make investments. 2017;127:1725–40.
Tanic N, Brkic G, Dimitrijevic B, Dedovic-Tanic N, Gefen N, Benharroch D, et al. Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell strains. Anticancer Res. 2006;26:2137–42.
Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G. Expressional patterns of chaperones in ten human tumor cell strains. Proteome Sci. 2004;2:8.
Hassin O, Nataraj NB, Shreberk-Shaked M, Aylon Y, Yaeger R, Fontemaggi G, et al. Completely different hotspot p53 mutants exert distinct phenotypes and predict consequence of colorectal most cancers sufferers. Nat Commun. 2022;13:2800.
Nakayama M, Oshima M. Mutant p53 in colon most cancers. J Mol Cell Biol. 2019;11:267–76.
Huang Y, Liu N, Liu J, Liu Y, Zhang C, Lengthy S, et al. Mutant p53 drives most cancers chemotherapy resistance attributable to lack of operate on activating transcription of PUMA. Cell Cycle. 2019;18:3442–55.
Rivlin N, Brosh R, Oren M, Rotter V. Mutations within the p53 tumor suppressor gene: necessary milestones on the numerous steps of tumorigenesis. Genes Most cancers. 2011;2:466–74.
Freed-Pastor WA, Prives C. Mutant p53: one identify, many proteins. Genes Dev. 2012;26:1268–86.
Zhao Y, Li Y, Sheng J, Wu F, Tune W. P53-R273H mutation enhances colorectal most cancers stemness via regulating particular lncRNAs. J Exp Clin Most cancers Res. 2019;38:379.
Garg A, Hazra JP, Sannigrahi M, Rakshit S, Sinha S. Variable mutations on the P53-R273 oncogenic hotspot place results in altered roperties. Biophys J. 2019;118:720–8.
Lei, J. Widespread most cancers mutations R175H and R273H drive the p53 DNA-binding area in the direction of aggregation-prone conformations. Phys Chem Chem Phys. 2020;22:23032.
Tan BS, Tiong KH, Choo HL, Fei-Lei Chung F, Hii LW, Tan SH, et al. Mutant p53-R273H mediates most cancers cell survival and anoikis resistance via AKT-dependent suppression of BCL2-modifying issue (BMF). Cell Loss of life Dis. 2015;6:e1826.
Rochette PJ, Bastien N, Lavoie J, Guérin SL, Drouin R. SW480, a p53 double-mutant cell line retains proficiency for some p53 features. J Mol Biol. 2005;352:44–57.
Ambrosini G, Adida C, Altieri DC, Ambrosini G, Adida C, Altieri DCA. novel antiapoptosis gene, survivin, expressed in most cancers and lymphoma. Nat Med. 1997;3:917–21.
Yoshida A, Zokumasu Okay, Wano Y, Yamauchi T, Imamura S, Takagi Okay, et al. Marked upregulation of survivin and aurora-B kinase is related to illness development within the myelodysplastic syndromes. Haematologica. 2012;97:1372–9.
Sah NK, Seniya C. Survivin splice variants and their diagnostic significance. Tumor Biol. 2015;36:6623–31.
Mirza A, Mcguirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–22.
Tang Q, Efe G, Chiarella AM, Leung J, Chen M, Yamazoe T, et al. Mutant p53 regulates survivin to foster lung metastasis. Genes Dev. 2021;35:528–41.
Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene household. Oncogene. 2004;23:8146–53.
Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in medical oncology: a multifaceted dragon. Med Res Rev. 2013;33:765–89.
Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Most cancers Lett. 2007;249:49–60.
Fedchenko N, Reifenrath J. Completely different approaches for interpretation and reporting of immunohistochemistry evaluation ends in the bone tissue – a overview. Diagn Pathol. 2014;9:221.
Roh SH, Kasembeli M, Bakthavatsalam D, Chiu W, Tweardy DJ. Contribution of the sort II chaperonin, TRiC/CCT, to oncogenesis. Int J Mol Sci. 2015;16:26706–20.
Boudiaf-Benmammar C, Cresteil T, Melki R. The cytosolic chaperonin CCT/TRiC and most cancers cell proliferation. PLoS One. 2013;8:e60895.
Vousden KH, Lu X. Reside or let die: the cell’s response to p53. Nat Rev Most cancers. 2002;2:594–604.
Vogelstein B, Lane D, Levine AJ. Browsing the p53 community. Nature. 2000;408:307–10.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Management of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–4.
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal most cancers: correlation with the prognosis and response to chemotherapy. Int J Most cancers. 2001;95:92–95.
Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. Excessive expression of survivin, mapped to 17q25, is considerably related to poor prognostic components and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–23.
Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival charges in colorectal most cancers. Most cancers Res. 1998;58:5071–4.
Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100–4.
Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Affiliation of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast most cancers. Oncogene. 2007;26:290–7.
Yang X, Xiong G, Chen X, Xu X, Wang Okay, Fu Y, et al. Survivin expression in esophageal most cancers: correlation with p53 mutations and promoter polymorphism. Dis Esophagus. 2009;22:223–30.
Pizem J, Cör A, Gale N. Survivin expression is a adverse prognostic marker in laryngeal squamous cell carcinoma and is related to p53 accumulation. Histopathology. 2004;45:180–6.
Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung most cancers. Int J Oncol. 2005;27:1215–21.
Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Most cancers Res. 2007;67:5999–6002.
Faivre J, Ponnelle T, Plenchette S, Chapusot C, Martin L, Piard F, et al. Mobile localisation of survivin: affect on the prognosis in colorectal most cancers. 2005;131:504–10.
Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, et al. Exploring the expression and prognostic worth of the TCP1 ring advanced in hepatocellular carcinoma and overexpressing Its s5 promotes HCC tumorigenesis. Entrance Oncol. 2021;11:739660.
Hassin O, Oren M. Drugging p53 in most cancers: one protein, many targets. Nat Rev Drug Discov. 2022;22:127–44.
Zache N, Lambert JMR, Rökaeus N, Shen J, Bykov VJN. Mutant p53 concentrating on by the low molecular weight compound STIMA-1. Mol Oncol. 2017;11:595–5.
Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff Okay, Kury S, et al. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, in opposition to human regular and most cancers cells by way of a caspase-9-dependent apoptosis. Most cancers Lett. 2015;359:211–7.
Sicari D, Fantuz M, Bellazzo A, Valentino E, Apollonio M, Pontisso I. et al. Mutant p53 improves most cancers cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene. 2019;38:6184–95.
Capaci V, Bascetta L, Fantuz M, Beznoussenko GV, Sommaggio R, Cancila V, et al. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat Commun. 2020;11:3945.
Walerych D, Lisek Okay, Sommaggio R, Piazza S, Ciani Y, Dalla E, et al. Proteasome equipment is instrumental in a typical gain-of-function program of the p53 missense mutants in most cancers. Nat Cell Biol. 2016;18:897–909.
Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004;23:7545–51.
Badran A, Yoshida A, Ishikawa Okay, Goi T, Yamaguchi A, Ueda T, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314:902–7.
Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SBSM, et al. Nuclear Survivin expression is correlated with malignant behaviors of head and neck most cancers along with aurora-B. Oral Oncol. 2010;46:263–70.
